Premium
Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis
Author(s) -
GarcíaGrimshaw Miguel,
JiménezRuiz Amado,
VegaBoada Felipe Arturo,
FalcónAntonio Orlando Emmanuel,
BarreraVargas Ana,
ValdésFerrer Sergio Iván
Publication year - 2021
Publication title -
neurology and clinical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2049-4173
DOI - 10.1111/ncn3.12457
Subject(s) - medicine , lupus nephritis , mycophenolate , lymphoma , primary central nervous system lymphoma , systemic lupus erythematosus , dermatology , nephritis , rituximab , central nervous system , immunology , disease , transplantation
Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for the induction and maintenance of lupus nephritis. The evidence regarding the development of PCNSL in patients with systemic lupus erythematosus (SLE) treated with MMF is limited to a few case reports. We present the case of a 40‐year‐old woman with a history of SLE who developed PCNSL while treated with MMF for lupus nephritis and a review of all published cases with this association.